Abstract
Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Current Molecular Medicine
Title: Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Volume: 9 Issue: 6
Author(s): Sarah Church, Bernard A. Fox, Walter J. Urba, Brendan D. Curti, Hong-Ming Hu, Todd S. Crocenzi, Sidney Rosenheim, Andrew D. Weinberg, Emmanuel Akporiaye, Edwin B. Walker, Daniel P. Haley, Elisa Cardenas, Ulf Petrausch, Kevin Friedman, Levi Maston, Tarsem Moudgil, Michael G. LaCelle, Sachin Puri, Ilka Assmann, James A. Thompson, Chris Twitty, Shawn M. Jensen and Christian H. Poehlein
Affiliation:
Abstract: Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Export Options
About this article
Cite this article as:
Church Sarah, Fox A. Bernard, Urba J. Walter, Curti D. Brendan, Hu Hong-Ming, Crocenzi S. Todd, Rosenheim Sidney, Weinberg D. Andrew, Akporiaye Emmanuel, Walker B. Edwin, Haley P. Daniel, Cardenas Elisa, Petrausch Ulf, Friedman Kevin, Maston Levi, Moudgil Tarsem, LaCelle G. Michael, Puri Sachin, Assmann Ilka, Thompson A. James, Twitty Chris, Jensen M. Shawn and Poehlein H. Christian, Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970670
DOI https://dx.doi.org/10.2174/156652409788970670 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Morphology of C6 Glioma Cells on a Water-Repellent Fractal Alkyl Ketene Dimer Surface
Current Nanoscience Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Nobiletin in Cancer Therapy; Mechanisms and Therapy Perspectives
Current Pharmaceutical Design A Peptide Based Pro-Drug Ameliorates Amyloid-β Induced Neuronal Apoptosis in In Vitro SH-SY5Y Cells
Current Alzheimer Research Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Radiotherapy and Its Impact on the Nervous System of Cancer Survivors
CNS & Neurological Disorders - Drug Targets